| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$47.3M | ROE | — |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $15.9M | Trading Days | 869 |
| 52W High | 3.05 |
| 52W Low | 0.25 |
| % Off High | −90.82% |
| YTD | −81.70% | 1Y | −88.52% |
| 3Y | −89.43% | 5Y | −89.43% |
| 10Y | 34900.00% | Since incept. (ann.) | 77.12% |
| Ann. Volatility (1Y) | 127.69% | Ann. Volatility (3Y) | 131.26% |
| Sharpe (1Y) | −1.06 | Sharpe (3Y) | −0.33 |
| Max Drawdown (1Y) | −90.18% | Max Drawdown (3Y) | −96.47% |
| Beta (3Y, vs SPY) | −0.51 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| CYCN | Cyclerion Therapeutics, Inc. | $15.2M | — |
| KTTA | Pasithea Therapeutics Corp. | $15.0M | — |
| SCNX | Scienture Holdings, Inc. | $14.9M | — |
| VYNE | VYNE Therapeutics Inc. | $17.0M | — |
| MDNAF | Medicenna Therapeutics Corp. | $17.1M | — |
| LPCN | Lipocine Inc. | $17.6M | — |
| CTXR | Citius Pharmaceuticals, Inc. | $14.2M | — |
| HIND | Vyome Holdings, Inc | $14.0M | — |
| CDT | CDT Equity Inc. | $18.0M | — |
| MBIO | MUSTANG BIO, INC. | $14.0M | — |
| BFRI | Biofrontera Inc. | $14.0M |
| — |
| TPST | Tempest Therapeutics, Inc. | $13.8M | — |
